Atezolizumab Monotherapy Vs Docetaxel In 2Nd And 3Rd Line Nsclc

Atezolizumab monotherapy vs docetaxel in 2nd and 3rd line NSCLC

POPLAR: Phase 2 trial of atezolizumab monotherapy in non-small cell lung cancer

EMJ

KEYNOTE 10: Pembrolizumab vs docetaxel for NSCLC

Dr. Wakelee on BIRCH Trial for Atezolizumab in Patients With NSCLC

Choices Among Immunotherapeutics May Be the Future of Lung Cancer Care

GRACE - Global Resource for Advancing Cancer Education

Dr. Melissa Johnson on Atezolizumab in Patients With NSCLC

Subgroup analysis of OAK trial data supports use of atezolizumab in patients with NSCLC

Atezolizumab for locally advanced or metastatic PD-L1-selected NSCLC

Significant survival gains with atezolizumab for NSCLC

Anti–PD-L1 atezolizumab or chemotherapy as second-line therapy in patients with SCLC

Second-Line Treatment in NSCLC

An Overview of the BIRCH Trial Investigating Atezolizumab in NSCLC

Targeted Oncology

Second-line treatment with ramucirumab plus docetaxel extends survival in advanced NSCLC

Phase 3 trials of atezolizumab versus standard chemotherapy in PD-L1-selected NSCLC

EMJ

Dr Melissa Johnson: Tiragolumab/Atezolizumab Potential New Treatment Option for NSCLC

First-, Second-, and Third-Line Treatment for NSCLC

BIRCH: Phase 2 trial of atezolizumab for advanced PD-L1-selected non-small cell lung cancer

EMJ

Results from a phase 3 study of 1L atezolizumab vs single-agent chemotherapy in pts with NSCLC

Dr. Borghaei on 2-Year Findings With Nivolumab Vs Docetaxel in NSCLC

#ESMO22 Highlights on first-line atezolizumab in NSCLC not eligible for platinum: The IPSOS study

European Society for Medical Oncology (ESMO)